Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LABTBullishCorporate Developmentsnews

Medium materiality6/10

Lakewood-Amedex Names Armstrong as Study Chair for Nu-3 iDFU Phase 2a

Jun 25, 2026, 8:09 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Credible clinical leadership can reduce execution risk, potentially improving enrollment and study design, which may support a positive re-rating if trial milestones are met or updated on timeline.

AI summary

What happened, with direct paths to the underlying reporting

Lakewood-Amedex Biotherapeutics named David G. Armstrong, a leading diabetic foot care expert, as Study Chair and Scientific Advisor for its Nu-3 Phase 2a trial in infected diabetic foot ulcers. The study will test 2%, 5%, and 10% doses to build evidence for advancement to Phase 2b, potentially boosting credibility and future value if results are favorable.

Dr. Armstrong named Study Chair for LABT's Phase 2a Nu-3 iDFU trial.
He will also serve as Scientific Advisor on LABT's iDFU program.
Phase 2a evaluates Nu-3 at 2%, 5%, and 10% doses.
Trial aims to support Phase 2b progression and assess safety/efficacy in iDFUs.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Lakewood-Amedex Names Armstrong as Study Chair for Nu-3 iDFU Phase 2a

Lakewood-Amedex's Nu-3 Advances Toward Phase 2 Clinical Trials